Acute myeloid leukemia trials in South Korea

In South Korea 16 Also abroad 761

16 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 1Enrolling by invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Where
Seoul
Age
18 years and over
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00
Phase 3Taking people
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Where
Daejeon, Goyang-si, Gyeonggi-do, Seoul
Age
18 years and over
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06852222 · EU 2024-520154-38-00
Phase 1/2Taking people
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Where
Seoul
Age
16 years and over
People
85 worldwide
Run by
AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00
Phase 2/3Taking people
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Where
Seongnam-si, Seoul
Age
18 years and over
People
660 worldwide
Run by
AbbVie
See details and how to joinNCT07581002 · EU 2025-523724-47-00
Phase 3Taking people
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Where
Busan, Daegu, Goyang-si, Seoul
Age
12 years and over
People
468 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00
Phase 3Taking people
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Where
Busan-si, Daegu, Daejeon, Hwasun, Namdong, Pusan, Seoul, Ulsan
Age
18 years and over
People
1,300 worldwide
Run by
Kura Oncology, Inc.
See details and how to joinNCT07007312 · EU 2025-521314-25-00
Phase 1Taking people
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Where
Seoul
Age
6 months to 17 years
People
18 worldwide
Run by
AbbVie
See details and how to joinNCT07306832
Phase 2Taking people
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Where
Busan, Daegu, Goyang-si, Incheon, Jeonju, Seongnam, Seoul, Suwon, Ulsan
Age
18 years and over
People
130 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06824168
Phase 1/2Taking people
A Study of BGB-11417 in Participants With Myeloid Malignancies
Where
GangnamGu, SeodaemunGu
Age
18 years and over
People
260 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00
No phaseTaking people
A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia
Where
Seoul
Age
19 years and over
People
165
Run by
Pfizer
See details and how to joinNCT05189639
Phase 1Taking people
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Where
Seoul
Age
18 years and over
People
260 worldwide
Run by
SillaJen, Inc.
See details and how to joinNCT05768932
Phase 1/2Taking people
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Where
Hwasun, Seoul
Age
12 years and over
People
606 worldwide
Run by
Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555
Phase 1Taking people
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia
Where
Incheon, Seoul
Age
18 years and over
People
150 worldwide
Run by
Lomond Therapeutics Holdings, Inc.
See details and how to joinNCT06366789
Phase 1/2Taking people
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Where
Daegu, Pusan, Seongnam, Seoul
Age
18 years and over
People
240 worldwide
Run by
Aptose Biosciences Inc.
See details and how to joinNCT03850574 · EU 2023-503244-14-00
Phase 3Enrolling by invitation
A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML.
Where
Seoul
Age
15 years to 60 years
People
380
Run by
Asan Medical Center
See details and how to joinNCT03507842
No phaseTaking people
A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia
Where
Seoul
Age
19 years and over
People
154
Run by
Bristol-Myers Squibb
See details and how to joinNCT06073769